Vaxart Inc Stock Price, News & Analysis

Vaxart (NASDAQ: VXRT) reported promising preliminary preclinical data for its COVID-19 vaccine candidates targeting the SARS-CoV-2 variants. Both the Wuhan and Omicron specific vaccines demonstrated protective effects in hamsters against the Omicron BA.1 variant, with the Omicron candidate showing superior antibody response. Weight loss and viral load were reduced in vaccinated animals compared to unvaccinated ones. Vaxart continues to leverage evolving pandemic data for vaccine development strategies, advancing toward clinical trials.

Vaxart (NASDAQ: VXRT) announced positive preliminary results from its Phase 1b trial of an oral norovirus vaccine for adults aged 55 to 80. The study showed a robust immune response with a dose-dependent increase in IgA antibody secreting cells, alongside a favorable safety profile. These results support the development of the vaccine in elderly populations. The company is conducting a Phase 2 clinical challenge study and reported encouraging data from a booster study, allowing for improved antibody responses. Norovirus costs the U.S. healthcare system an estimated $10.6 billion annually.

Vaxart, Inc. (Nasdaq: VXRT) announced that its leadership team, including CEO Andrei Floroiu, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. The event will be streamed live on the Company’s website, with a replay available afterward. Vaxart specializes in developing oral recombinant vaccines and is currently working on vaccines targeting coronavirus, norovirus, seasonal influenza, and RSV, among others. The company is committed to innovative delivery methods for vaccines that require no refrigeration.

Vaxart (NASDAQ: VXRT) announced significant findings from a preclinical hamster study, suggesting its S-only oral COVID-19 vaccine candidate effectively inhibits SARS-CoV-2 transmission. The study highlighted a reduction in infectious virus and transmission among vaccinated hamsters. Additionally, Phase 1 results showed the S+N vaccine candidate stimulated cross-reactive IgA antibodies, indicating potential effectiveness against various coronaviruses. The results were published in Science Translational Medicine, reinforcing Vaxart's oral vaccine development strategy. Future Phase II results are expected later this year.

Vaxart, Inc. (NASDAQ: VXRT) reported an update for Q1 2022, highlighting progress on oral vaccine candidates, including norovirus and COVID-19. The company ended the quarter with $157.0 million in cash and reported a net loss of $25.1 million, up from $16.0 million a year prior. Revenue fell to $85,000 from $506,000 year-over-year, primarily due to decreased royalty revenue. Key results from clinical trials for its COVID-19 and norovirus vaccines are expected in the upcoming quarters.

Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 on April 20, 2022, at 3:55 p.m. ET. His presentation is titled “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.” Dr. Tucker will share data highlighting the potential benefits of Vaxart’s oral tablet COVID-19 vaccine candidate, which is currently in clinical development.

Vaxart develops oral recombinant vaccines that can be stored without refrigeration, aiming to create vaccines for various diseases, including coronavirus and HPV.

Vaxart, Inc. (NASDAQ: VXRT) provides a business update, reporting a net loss of $70.5 million for 2021 compared to $32.2 million in 2020. Revenue dropped to $892,000 from $4.0 million. As of December 31, 2021, the company had $182.7 million in cash and equivalents. Significant advancements in COVID-19 and norovirus vaccine programs are ongoing, with Phase II trials underway. Key data readouts are expected in 2022, including initial results from the COVID-19 vaccine trials and norovirus studies.

A recent study on Vaxart’s S-only COVID-19 vaccine candidate has shown promising results, demonstrating cross-reactivity against multiple variants including beta, delta, alpha, and gamma. The vaccine, now in Phase II trials, induced a remarkable 1,000-fold increase in nasal IgA responses, potentially reducing community transmission. Unlike current vaccines, this candidate effectively generates antibodies at mucosal sites where infections occur, suggesting enhanced protection against variants, particularly omicron. The data indicates robust antibody responses, positioning Vaxart's candidate as a significant advancement in vaccine development.

Vaxart, Inc. (NASDAQ: VXRT) has appointed Edward B. Berg as its first in-house General Counsel, effective immediately. With over 30 years of legal experience, Berg joins Vaxart from BioMarin Pharmaceutical, where he was VP and Deputy General Counsel. His extensive background in biotechnology and pharmaceuticals is expected to strengthen Vaxart's leadership team, enhancing the company’s ability to address regulatory and compliance challenges as it develops innovative oral vaccines. The appointment reflects Vaxart's commitment to public health and its mission to improve vaccination accessibility worldwide.